Summary
We have previously demonstrated the ability of reovirus to function synergistically with chemotherapy in the treatment of murine EL-4 lymphoma. This study characterizes this treatment regimen in the therapy of L1210 leukemia. Animals with an estimated tumor burden of 107 cells were treated with 9 mg/kg 1,3-bis(2-chloroethyl)-1-nitrosourea. Reovirus type 3, which had been quantitated either by particles or plaque-forming units (pfu), was administered 48 h after chemotherapy. Complete remission of tumor was observed in 80% of the animals which received either 1011 particles or 109 pfu of reovirus. Cured animals were resistant to challenge with homologous tumor, but were susceptible to challenge with heterologous tumor. Reovirus undergoes limited replication at the tumor site, and virus-specific antibody appears only after disappearance of reovirus-infected cells and virus from the ascites fluid. Reovirus appears to function therapeutically by inducing a tumor-specific cytolytic immune response.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Austin FC, Boone CW (1979) Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res 30:31
Berendt MJ, North RJ (1980) T-cell-mediated suppression of anti-tumor immunity: an explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69
Byrne JA, Soloski M, Holowczak JA (1983) Immune responses of DBA/2 mice bearing melanoma tumors: cell-mediated immune responses after challenge with vaccinia virus. Cancer Immunol Immunother 16:81
Duncan MR, Stanish SM, Cox DC (1978) Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28:444
Epstein LB, McManus NH (1980) Macro- and microassays for the antiviral effects of human and mouse interferons. In: Manual of clinical immunology 2nd edn. Am Soc Microbiol, Washington, p 275
Hayes EC, Lee PW, Miller SE, Joklik WK (1981) The interaction of a series of hybridoma IgGs with reovirus particles. Demonstration that the core protein lambda 2 is exposed on the particle surface. Virology 108:147
Hersey P, Edwards A, D'Alessandro G, MacDonald M (1986) Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. Cancer Immunol Immunother 22:221
Kobayashi H (1979) Viral xenogenization of intact tumor cells. Adv Cancer Res 30:279
Kobayashi H (1982) Modification of tumor antigenicity in therapeutics: Increase in immunologic foreignness of tumor cells in experimental model systems. In: Mihich E (ed) Immunological approaches to cancer therapeutics. John Wiley and Sons, New York, p 405
Kobayashi H (1986) The biological modification of tumor cells as a means of inducing their regression: an overview. J Biol Response Mod 5:1
Kollmorgen GM, Sansing WA, Cantrell JL, Killion JJ, Bundren JC (1975) Treatment of murine lymphocytic leukemia with BCNU, VCN-treated cells and BCG. In: Neoplasm immunity: theory and application. ITR Press, p 27
Kollmorgen GM, Sansing WA, Cox DC, Killion JJ, Cantrell JL (1976) Induction of immunity with immunotherapy. In: Crispen RG (ed) Neoplasm immunity: mechanisms. ITR Press, Chicago, p 25
Kollmorgen GM, Cox DC, Killion JJ, Cantrell JL, Sansing WA (1976) Immunotherapy of EL-4 lymphoma with reovirus. Cancer Immunol Immunother 1:239
Lotzova E, Savary CA, Freedman RS, Bowen JM (1984) Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract. Cancer Immunol Immunother 17:124
Molomut N, Padnos M, Papperman TW, Pevear DC, Pfau DJ (1984) Immune recognition of tumor cells in mice infected with Pichinde virus. Cancer Immunol Immunother 17:56
Nagarkatti M, Kaplan AM (1985) The role of suppressor T cells in BCNU-mediated rejection of syngeneic tumor. J Immunol 135:1510
Natuk RJ, Byrne JA, Holowczak JA (1986) Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells. Cancer Immunol Immunother 22:197
Oldham RK (1983) Biological response modifiers. J Natl Cancer Inst 70:789
Shaw JE, Cox DC (1973) Early inhibition of cellular DNA synthesis by high multiplicities of infectious and UV-inactivated reovirus. J Virol 12:704
Smith RE, Zweerink HJ, Joklik WK (1969) Polypeptide components of virions, top component, and cores of reovirus type 3. Virology 39:791
Wakamiya N, Wang Y-L, Imai H, Gu H-X, Ueda S, Kato S (1986) Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity. Cancer Immunol Immunother 23:125
Williams ME, Cox DC, Stevenson JR (1986) Rejection of reovirus-treated L1210 leukemia cells by mice. Cancer Immunol Immunother 23:87
Wise K (1977) Vesicular stomatitis virus-infected L1210 murine leukemia cells: Increased immunogenicity and altered surface antigens. J Natl Cancer Inst 58:83
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bryson, J.S., Cox, D.C. Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia. Cancer Immunol Immunother 26, 132–138 (1988). https://doi.org/10.1007/BF00205606
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00205606